Search results
Results from the WOW.Com Content Network
AMAG Pharmaceuticals (AMAG) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AMAG Pharmaceuticals (AMAG) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
AMAG's main product, Ferumoxytol was estimated by the company to generate revenue of $71.5 million in 2013. [5] In August 2013, the company received a new U.S. patent for Ferumoxytol, expiring in 2020. [6] In June 2015, the company acquired Cord Blood Registry for $700 million. [7] In 2014, AMAG acquired Lumara Health, formerly KV ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Since April 8, 2011, the shares of AMAG Austria Metall AG have been traded on the official market (Prime Market) of the Vienna Stock Exchange under the ticker symbol "AMAG". From September 24, 2012 to September 23, 2013, the company was represented in the ATX.